Table 1

Therapy for rheumatoid arthritis: unmet needs

Problem

Details


Heterogeneity of the disease

Some patients respond to DMARD monotherapy

Not every patient responds to anti-TNF (mono or combination) therapy

'Remission' rates

What is the pathology/biologic process in each individual patient?

Toxicities

Infections, immunogenecity, congestive heart failure, drug-induced vasculitis, etc

Costs

Limits availability to may patients


DMARD, disease-modifying antirheumatic drug; TNF, tumor necrosis factor.

Moreland Arthritis Research & Therapy 2005 7(Suppl 3):S2-S8   doi:10.1186/ar1736